¿Por qué es tan difícil publicar resultados negativos?

  • Fernando Lamata Doctor en Medicina. Miembro de la Asociación por un acceso justo al medicamento.
Palabras clave: -

Resumen

-

Citas

Stephens J. Where profits and lives hang in Balance. The Body Hunters. The Washington Post, Dec 17, 2000.

Stephens J. Panel Faults Pfizer in ’96 Clinical Trial in Nigeria. The Washington Post, May 7 2006.

Stephens J. Pfizer to Pay $75 Million to Settle Nigerian Trovan Drug- Testing Suit. The Washington Post. July 31, 2009.

Laporte JR. Las supuestas ventajas de celecoxib y rofecoxib: fraude científico. Butlletí groc. Julio-Septiembre 2002; 15 (Nº4): 13-15

Bruckner T, Ellis B. Clinical Trial Transparency: A Key to Better and Safer Medicines. Working Paper. April 2017. DOI: 10.13140/RG.2.2.21249.35686

Hampton J. Therapeutic fashion and publication bias: the case of anti- arrhythmic drugs in heart attack. JLL Bulletin: Commentaries on the story of treatment evaluation. 2015.

Ioanidis J. Why most clinical research is not useful. PloSMed 13(6):e1002049. Doi:10.1371/journal.pmed.1002049. June 21,2016.

Courtney D et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study fo drug appovals 2009-13. BMJ 2017;

:j4530 doi:10.1136/bmj.j4530

Angells M. The truth about the drug companies: how they deceive us and what to do about it. New York. Random House. 2004.

EFPIA. The pharmaceutical industry in figures. Key data 2017.

Baker D. Bird Flu Fears: Is there a better way to develop drugs? CEPR Issue brief. October 2005.

Lamata F, Gálvez R, Sánchez-Caro J, Pita Barros P, Puigventós F. Medicamentos: ¿derecho humano o negocio? Díaz de Santos. Madrid, 2017.

UN Secretary-General’s High-Level Panel on Access to Medicines Report, 14 September 2016.

Publicado
2018-03-18